Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572

Watchlist Manager
Zhejiang CONBA Pharmaceutical Co Ltd Logo
Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572
Watchlist
Price: 4.68 CNY -2.09% Market Closed
Market Cap: 11.7B CNY
Have any thoughts about
Zhejiang CONBA Pharmaceutical Co Ltd?
Write Note

Zhejiang CONBA Pharmaceutical Co Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zhejiang CONBA Pharmaceutical Co Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
Zhejiang CONBA Pharmaceutical Co Ltd
SSE:600572
Total Current Assets
ÂĄ4.9B
CAGR 3-Years
7%
CAGR 5-Years
0%
CAGR 10-Years
8%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Current Assets
ÂĄ28.9B
CAGR 3-Years
19%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Current Assets
ÂĄ15.1B
CAGR 3-Years
15%
CAGR 5-Years
17%
CAGR 10-Years
21%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Current Assets
ÂĄ34.8B
CAGR 3-Years
5%
CAGR 5-Years
10%
CAGR 10-Years
18%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Current Assets
ÂĄ36.4B
CAGR 3-Years
-8%
CAGR 5-Years
-3%
CAGR 10-Years
11%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Current Assets
ÂĄ775.8m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Zhejiang CONBA Pharmaceutical Co Ltd
Glance View

Market Cap
11.8B CNY
Industry
Pharmaceuticals

Zhejiang CONBA Pharmaceutical Co., Ltd. stands as a prominent figure in the vast landscape of China's pharmaceutical industry. This enterprise, established in the economically vibrant province of Zhejiang, has carved its niche through rigorous adherence to research-driven innovation and quality assurance. While the pharmaceutical realm is competitive and challenging, CONBA has made strategic inroads by focusing on both modern medicine and traditional Chinese medicine (TCM). This dual approach has allowed the company to tap into a rich tapestry of healthcare solutions, catering to diverse consumer needs. By leveraging a robust research and development framework, CONBA continues to enhance its portfolio, offering a wide array of medicinal products including prescription drugs, over-the-counter medications, and healthcare supplements. Financially, Zhejiang CONBA thrives through a multifaceted business model. The company's revenue streams are bolstered by its strong domestic market presence alongside its expanding international footprint. It strategically combines manufacturing prowess with an extensive distribution network, ensuring that its products are readily accessible. Moreover, CONBA's commitment to quality and compliance with international regulatory standards has fostered trust and reinforced its brand reputation both within and outside of China. As it continues to evolve, CONBA remains dedicated to harnessing advancements in biotechnology and pharmacology, aiming to sustain profitability while contributing to the global healthcare dialogue.

Intrinsic Value
8.12 CNY
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Zhejiang CONBA Pharmaceutical Co Ltd's Total Current Assets?
Total Current Assets
4.9B CNY

Based on the financial report for Sep 30, 2024, Zhejiang CONBA Pharmaceutical Co Ltd's Total Current Assets amounts to 4.9B CNY.

What is Zhejiang CONBA Pharmaceutical Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
8%

Over the last year, the Total Current Assets growth was -14%. The average annual Total Current Assets growth rates for Zhejiang CONBA Pharmaceutical Co Ltd have been 7% over the past three years , and 8% over the past ten years .

Back to Top